SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (583)4/8/1999 5:54:00 PM
From: scaram(o)ucheRead Replies (1) of 4974
 
"The most frequently reported adverse events were tiredness and drowsiness"

Too bad. And I had such high hopes for this candidate.

- g -

biz.yahoo.com

I'll nominate completion of the Phase Ib multiple dose,
dose-escalating study for NBI-34060, a GABA(A) receptor subtype agonist.

Also, GENXY delivered to Synthelabo a third gene in its prostate program, triggering a milestone payment. More progress from positional cloning.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News